| Year | Randomized | % of Goal | # of Trials |
|---|---|---|---|
| 2019 | 1148 | 119% | 14 |
| 2018 | 248 | 105% | 5 |
| 2017 | 335 | 98% | 5 |
| 2016 | 326 | 137% | 4 |
| 2015 | 487 | 122% | 6 |
| 2014 | 731 | 110% | 9 |
| 2013 | 491 | 115% | 6 |
| 2012 | 345 | 108% | 4 |
| 2011 | 331 | 115% | 5 |
| 2010 | 267 | 113% | 5 |
| 2009 | 581 | 98% | 8 |
| 2008 | 624 | 114% | 7 |
| Total: | 4766 | 112% | 78 |
| Year | Type | Age | % of Goal | Randomized | Enrollment Days | Retention Rate |
|---|---|---|---|---|---|---|
| 2019 | C. Diff | 50+ | 102% | 61 | 425 | TBD |
| 2019 | Influenza | 18-30 | 100% | 50 | 1 | 100 |
| 2019 | Pneumococcal | 18-49 | 100% | 45 | 18 | 100 |
| 2019 | RSV | 18-45 | 103% | 154 | 25 | 100 |
| 2019 | Pneumococcal | 50+ | 108% | 40 | 90 | 92% |
| 2019 | Smallpox | 18-45 | 118% | 177 | 62 | TBD |
| 2019 | C. Diff | 50+ | 175% | 21 | 150 | TBD |
| 2019 | E Coli | 60 -80 | 112% | 76 | 90 | TBD |
| 2019 | Lyme | 18-65 | 101% | 76 | 60 | 100 |
| 2019 | Lyme | 18-70 | 222% | 133 | 270 | 97% |
| 2019 | Pneumococcal | 18-64 | 105% | 63 | 94 | 98 |
| 2019 | Pneumococcal | 18-49 | 100% | 58 | 4 | 98% |
| 2019 | RSV | 18-40 and 60-80 | 102% | 178 | 60 | TBD |
| 2019 | Meningitis | 2 Month Olds | TBD | 16 | 365 | 100 |
| 2018 | Pneumococcal | 50+ | 120% | 48 | 43 | 100% |
| 2018 | HPV | 27+ | 100% | 3 | 35 | 100% |
| 2018 | Zika | 18-49 | 105.0% | 42 | 32 | 92% |
| 2018 | Dengue | 18-50 | 97.0% | 34 | 72 | 87% |
| 2018 | Avian Flu | 18-49 | 102% | 122 | 43 | 66% |
| 2017 | Influenza | 18-39 | 95% | 104 | 118 | 73% |
| 2017 | Influenza | 18-49 | 102% | 92 | 16 | 87% |
| 2017 | Influenza | 65+ | 105% | 77 | 8 | 99% |
| 2017 | Cholera | 2 yrs - 8 yrs | 100% | 40 | 112 | 79% |
| 2017 | Meningitis | 10 yrs -26 yrs | 88% | 22 | 171 | 77% |
| 2016 | Herpes | 18-50 | 193% | 29 | 200 | 73% |
| 2016 | Avian Flu | 18+ | 120% | 180 | 45 | 99% |
| 2016 | Meningitis | 15+ | 111% | 30 | 47 | 100% |
| 2016 | Avian Flu | 18-49 | 124% | 87 | 16 days | 86% |
| 2015 | RSV | 60+ | 129% | 246 | 37 | 100% |
| 2015 | Pneumococcal | 65+ | 128% | 32 | 51 | 100% |
| 2015 | Pneumococcal | 18-49 | 100% | 20 | 8 | 100% |
| 2015 | Tetanus | 19-64 | 98% | 44 | 80 | 100% |
| 2015 | Influenza | 65+ | 117% | 105 | 20 | 100% |
| 2015 | Ebola | 18-65 | 160% | 40 | 39 | 95% |
| 2014 | Influenza | 50+ | 135% | 303 | 61 | 99% |
| 2014 | Influenza | 18-49 | 100% | 63 | 16 | 100% |
| 2014 | Influenza | 18-49 | 73% | 22 | 20 | 100% |
| 2014 | Pneumococcal | 50+ | 135% | 27 | 24 | 100% |
| 2014 | Pneumococcal | 50+ | 90% | 18 | 72 | 94% |
| 2014 | Norovirus | 18-49 | 102% | 56 | 30 | 82% |
| 2014 | Cholera | 18-45 | 157% | 157 | 80 | 93% |
| 2014 | HPV | 12 yrs -26 yrs | 100% | 3 | 30 | 33% |
| 2014 | Influenza | 18-40 | 102% | 82 | 73 | 98% |
| 2013 | Influenza | 18+ | 100% | 70 | 14 | 99% |
| 2013 | Meningitis | 10 yrs - 19 yrs | 115% | 23 | 193 | 87% |
| 2013 | Influenza | 21-64 | 100% | 49 | 33 | 96% |
| 2013 | Influenza | 65+ | 95% | 55 | 105 | 94% |
| 2013 | Smallpox | 18-40 | 170% | 196 | 116 | 100% |
| 2013 | Influenza | 18+ | 109% | 98 | 10 | 100% |
| Total: | 115% | 3767 | 62 | 91% |
| Indication | # of Trials | Randomized | % of Goal |
|---|---|---|---|
| Anthrax | 1 | 59 | 118% |
| Avian Flu | 10 | 857 | 103% |
| C Diff | 3 | 82 | 107% |
| Cholera | 2 | 197 | 129% |
| Dengue | 1 | 34 | 97% |
| Ebola | 1 | 40 | 160% |
| E. Coli | 1 | 76 | 112% |
| Hep B | 1 | 125 | 208% |
| Herpes | 1 | 29 | 193% |
| HPV | 4 | 43 | 105% |
| Influenza | 32 | 2473 | 98% |
| Lyme Disease | 2 | 209 | 162% |
| Meningitis | 6 | 197 | 99% |
| Norovirus | 1 | 56 | 102% |
| Plague | 1 | 40 | 108% |
| Pneumococcal | 15 | 497 | 143% |
| RSV | 9 | 798 | 122% |
| Smallpox | 2 | 373 | 150% |
| Tetanus | 2 | 62 | 80% |
| Zika | 1 | 42 | 105% |
| Zoster | 1 | 3 | 75% |
| Total: | 97 | 6292 | 123% |
| Age Group | # of Trials | % of Trials |
|---|---|---|
| Pediatric/Adolescent | 13 | 13% |
| Adult | 54 | 56% |
| Elderly | 30 | 31% |
| Total: | 97 | 100% |